Affimed N.V 1-Jahres-Ziel

Was ist das 1-Jahres-Ziel von Affimed N.V?

1-Jahres-Ziel von Affimed N.V. ist $7 +75.02%

Was ist die Definition von 1-Jahres-Ziel?

1-Jahres-Ziel ist ein prognostizierter Aktienkurs pro Jahr.

One year target is an estimate of a stock price for a point in time equal to a year from the current date. The price level most often reflects the collective opinion of different analysts on where the stock will be trading a year from now. For an analyst to identify an individual estimate, they have to project what a company’s business will look like in a year, typically focusing on revenue and other significant factors. They also consider the willingness of investors to pay a certain price. While the average or median recommendation may be predictive and reflect the actual future value, the results are usually not extremely successful.

1-Jahres-Ziel von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Affimed N.V

Was macht Affimed N.V?

affimed (symbol: afmd) is a nasdaq-listed clinical-stage biopharmaceutical company focused on discovering and developing targeted immuno-oncology therapies. immuno-oncology represents a highly promising approach to cancer treatment that seeks to harness the body’s own immune defenses to attack and destroy tumor cells. natural killer cells, or nk-cells, and t-cells belong to the most potent cells of the human defense arsenal. affimed’s proprietary, next-generation bispecific antibodies, termed tandabs®, are designed to bring nk-cells or t-cells into close proximity to cancer cells that ultimately triggers a signal cascade that leads to the destruction of cancer cells. due to their novel tetravalent tandem architecture, which provides for four binding domains, the tandabs bind to specific targets on immune and cancer cells with high affinity. in addition, tandabs exhibit kinetic properties allowing the administration as regular intravenous infusion and fine-tuning of dosing. affimed beli

Unternehmen mit 1-jahres-ziel ähnlich Affimed N.V